Our Pipeline

We’re focused on the innovative application of science and medicine

With patients at the center of everything we do, Sunovion has charted new paths to life-transforming treatments that reflect our ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurologic and respiratory disorders.

Candidate Indication/Target Phase
001 SUN-101/eFlow® Chronic obstructive pulmonary disease (COPD) Registration (U.S.)
002 Lurasidone HCl Bipolar depression, children and adolescents Registration (U.S., Canada)
003 Eslicarbazepine acetate Partial-onset seizures, pediatric (monotherapy) Registration (Canada)
004 Eslicarbazepine acetate Partial-onset seizures, pediatric (monotherapy/adjunctive therapy) Registration (Canada)
005 Dasotraline Attention deficit hyperactivity disorder (ADHD), adult and pediatric Registration (U.S.)
006 Dasotraline Binge eating disorder, adult Phase 3
007 APL-130277 OFF episodes associated with Parkinson’s disease Phase 3
008 SB623 Chronic stroke Phase 2
009 SEP-363856 Schizophrenia Phase 2
010 SEP-363856 Parkinson’s disease psychosis Phase 2
011 DSP-2230 Neuropathic pain Phase 1
012 WT-2725 Hematologic and solid cancer Phase 1
013 DSP-1200 Treatment-resistant depression Phase 1
014 DSP-6745 Parkinson's disease psychosis Phase 1
015 SEP-378608 Bipolar depression Phase 1